je.st
news
Tag: hiv
Quick start to HIV drug treatment can cut risk of illness, death in half
2015-05-29 12:11:26| Biotech - Topix.net
A large clinical trial confirms that HIV-positive patients are less likely to become seriously ill or die if they begin treatment with antiretroviral drugs right away. Above, capsules of the antiretroviral drug Indinavir.
Dust, TB and HIV: the ugly face of mining in South Africa
2015-05-26 07:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Guardian: Worried that his eyes and urine were turning a deep yellow, Gednezar Dladla made his way to a local clinic and was referred to a district hospital, where he was x-rayed, diagnosed with gallstones, and admitted for the night. Both institutions receive funding from the Wellcome Trust and the Bill & Melinda Gates Foundation. A day later, Dladla set off through the hills and valleys of rural Zululand to a village near his childhood home, where a group of men played cards in the shade of a tree. The...
Glaxo scraps float plan for HIV unit
2015-05-06 15:56:22| BBC News | Business | UK Edition
UK pharmaceuticals firm GlaxoSmithKline decides to keep its full stake in ViiV Healthcare after robust sales of the units HIV drugs.
GlaxoSmithKline opts to hold on to HIV business
2015-05-06 15:04:10| Biotech - Topix.net
British-based drugmaker GlaxoSmithKline has opted to keep its stand-alone HIV business as it set out its strategy following the completion of its recent deal with Switzerland's Novartis. GSK said it has cancelled an initial public offering of its HIV business, ViiV Healthcare, opting instead to retain its full holding in the joint venture with equity partners Pfizer and Shiongi.
Tags: business
hold
hiv
glaxosmithkline
Gilead's low-dose, high-impact HIV drug heads to the FDA
2015-04-08 05:46:56| Biotech - Topix.net
A next-generation HIV drug from Gilead Sciences Inc. , which could be more effective and have fewer side effects with a lower dosage, will go to federal regulators for a decision on whether it should be approved. The drug - a combination of Gilead's emtricitabine and tenofovir alafenamide, or TAF - is the second so-called F/TAF drug submitted by the Foster City-based company to the Food and Drug Administration.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] next »